Ensysce Biosciences has received a $5.3 million installment from the National Institute on Drug Abuse to support the development of its MPAR overdose-protection technology and lead product candidate, PF614-MPAR.
The latest award represents the third consecutive year of funding under a multi-year federal grant totaling approximately $15.1 million. The installment completes the full grant award and will support the continued nonclinical and clinical development of Ensysce’s opioid safety platform.
Ensysce is a clinical-stage pharmaceutical company developing pain and central nervous system treatments designed to reduce the risks of drug abuse and overdose.
The company plans to use the funding to complete its PF614-MPAR-102 clinical study and conduct the long-term nonclinical studies needed for a potential New Drug Application submission to the U.S. Food and Drug Administration.
PF614-MPAR is a first-in-class opioid product candidate designed to provide pain relief while actively limiting opioid exposure when a patient takes more pills than prescribed.
The investigational therapy has received Breakthrough Therapy designation from the FDA following the agency’s review of initial clinical data from Ensysce’s PF614-101 study.
Traditional abuse-deterrent opioid formulations are generally designed to make pills more difficult to crush, dissolve, inject, or otherwise manipulate. However, these approaches may not prevent an overdose when multiple intact pills are swallowed.
Ensysce’s MPAR technology is designed specifically to address oral overdose risk. The platform uses a proprietary chemical control mechanism that maintains therapeutic opioid exposure during prescribed use while restricting the release of additional opioid when excessive quantities are ingested.
The company describes the mechanism as a built-in safety switch that can help control drug exposure during intentional misuse, accidental overconsumption, or dosing errors.
Ensysce believes the approach could establish a new category of opioid medicines engineered to provide both effective pain relief and active overdose protection.
The $15.1 million NIDA award has supported the development of the MPAR platform through nonclinical testing and human clinical studies. The third-year installment reflects continued federal support as the program advances toward later-stage development.
PF614-MPAR combines Ensysce’s PF614 opioid prodrug with its Multi-Pill Abuse Resistance technology.
PF614 is based on the company’s Trypsin-Activated Abuse Protection platform, which is designed to keep an opioid inactive until it reaches the small intestine and is exposed to the digestive enzyme trypsin.
This activation mechanism is intended to make the drug more difficult to misuse through alternative routes of administration. MPAR adds a separate overdose-protection mechanism intended to limit opioid release when excessive doses are swallowed.
Together, the technologies are designed to address both manipulation-based abuse and oral overdose, two of the most significant risks associated with prescription opioid treatment.
Ensysce is initially developing PF614-MPAR for patients who require treatment for severe pain. The company believes safer opioid options remain necessary for patients whose pain cannot be adequately managed through non-opioid treatments.
The development program comes amid the continuing opioid overdose crisis in the United States. Ensysce noted that nearly 80,000 people die from opioid overdoses annually, with prescription opioids continuing to contribute to the public health burden.
Although PF614-MPAR is intended to reduce overdose risk, the product remains investigational and has not been approved by the FDA. Additional studies will be required to establish its safety and effectiveness and support a potential regulatory submission.
The FDA’s Breakthrough Therapy designation is intended to accelerate the development and review of therapies that may provide substantial improvement over available treatments for serious or life-threatening conditions.
The designation can provide sponsors with more frequent interaction and guidance from the FDA as they design clinical studies and prepare regulatory submissions. It does not guarantee that a product will ultimately receive approval.
Beyond prescription pain treatments, Ensysce believes its TAAP and MPAR technologies could be applied to other medications with abuse or overdose risks.
The company is exploring potential applications involving amphetamines and methadone. These programs could support the development of safer treatments for attention-deficit/hyperactivity disorder and opioid use disorder.
Methadone is commonly used to treat opioid use disorder and certain forms of severe pain, but excessive exposure can cause serious respiratory depression and overdose. Ensysce believes its chemical protection technologies could help control exposure during misuse.
Amphetamine-based medications are widely used for ADHD but also carry risks of misuse and excessive dosing. The company is evaluating whether its platforms could be adapted to create treatments with additional built-in safeguards.
Ensysce’s broader strategy is to use chemistry to alter how medications are activated or released in the body rather than relying solely on external monitoring, packaging, or patient behavior to reduce abuse.
The newly awarded funding will allow the company to continue generating the clinical and nonclinical evidence needed to advance PF614-MPAR toward a potential late-stage development program and regulatory submission.
KEY QUOTE:
“This continued NIDA funding allows us to keep advancing MPAR, a new class of chemically engineered opioids designed to actively safeguard patients, even in situations involving misuse or dosing mistakes. This innovation marks an important step toward setting a new standard for opioid safety.”
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences
